Fabien Zoulim, MD, PhD

Hospital Croix Rousse
Lyon, Rhone-Alpes, France

Disclosure(s): Aligos Therapeutics: consulting fees; Antios Therapeutics: consulting fees; Assembly Biosciences: consulting fees, Grant/Research Support; Beam Therapeutics: Grant/Research Support; Gilead Sciences, Inc.: consulting fees; Janssen: Grant/Research Support

Presentation(s):

• 83 - Predictors of Undetectable HDV RNA 48 weeks after completion of finite treatment with Bulevirtide and Pegylated-Interferon Alpha 2a

  Thursday, October 17, 2024
  10:45 AM – 11:00 AM US PT